CN1312148C - 用于治疗中枢神经系统疾病的异色满化合物 - Google Patents

用于治疗中枢神经系统疾病的异色满化合物 Download PDF

Info

Publication number
CN1312148C
CN1312148C CNB028281209A CN02828120A CN1312148C CN 1312148 C CN1312148 C CN 1312148C CN B028281209 A CNB028281209 A CN B028281209A CN 02828120 A CN02828120 A CN 02828120A CN 1312148 C CN1312148 C CN 1312148C
Authority
CN
China
Prior art keywords
dihydro
compound
ethyl
hydrogen
benzopyran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028281209A
Other languages
English (en)
Chinese (zh)
Other versions
CN1620447A (zh
Inventor
J·阿格贾斯－希查尔罗
A·B·布伊恩梅伦多
N·P·坎普
J·吉查雷
C·拉马斯-佩泰拉
G·H·蒂姆斯
A·C·威廉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1620447A publication Critical patent/CN1620447A/zh
Application granted granted Critical
Publication of CN1312148C publication Critical patent/CN1312148C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB028281209A 2001-12-19 2002-12-06 用于治疗中枢神经系统疾病的异色满化合物 Expired - Fee Related CN1312148C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0130339.5 2001-12-19
GBGB0130339.5A GB0130339D0 (en) 2001-12-19 2001-12-19 Isochroman compounds

Publications (2)

Publication Number Publication Date
CN1620447A CN1620447A (zh) 2005-05-25
CN1312148C true CN1312148C (zh) 2007-04-25

Family

ID=9927920

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028281209A Expired - Fee Related CN1312148C (zh) 2001-12-19 2002-12-06 用于治疗中枢神经系统疾病的异色满化合物

Country Status (20)

Country Link
EP (1) EP1458703B1 (enExample)
JP (1) JP2005516952A (enExample)
CN (1) CN1312148C (enExample)
AR (1) AR038662A1 (enExample)
AT (1) ATE355283T1 (enExample)
AU (1) AU2002359378B8 (enExample)
BR (1) BR0214859A (enExample)
CA (1) CA2469278A1 (enExample)
CY (1) CY1106552T1 (enExample)
DE (1) DE60218529T2 (enExample)
DK (1) DK1458703T3 (enExample)
ES (1) ES2280606T3 (enExample)
GB (1) GB0130339D0 (enExample)
MX (1) MXPA04006085A (enExample)
PE (1) PE20030728A1 (enExample)
PT (1) PT1458703E (enExample)
SI (1) SI1458703T1 (enExample)
SV (1) SV2004001441A (enExample)
TW (1) TW200301116A (enExample)
WO (1) WO2003053948A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
NL2000351C2 (nl) 2005-12-22 2007-09-11 Pfizer Prod Inc Estrogeen-modulatoren.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4247553A (en) * 1977-10-31 1981-01-27 The Upjohn Company Methods of treating psychosis
CN1139431A (zh) * 1993-12-28 1997-01-01 厄普约翰公司 用于治疗中枢神经系统和心血管疾病的杂环化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9710260A (es) * 1995-06-30 1998-03-29 Upjohn Co Isocromanos 1, 6-disustituidos para el tratamiento de migrañas.
GB2370270A (en) * 2000-12-20 2002-06-26 Lilly Co Eli Pharmaceutical compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4247553A (en) * 1977-10-31 1981-01-27 The Upjohn Company Methods of treating psychosis
CN1139431A (zh) * 1993-12-28 1997-01-01 厄普约翰公司 用于治疗中枢神经系统和心血管疾病的杂环化合物

Also Published As

Publication number Publication date
MXPA04006085A (es) 2004-09-27
SI1458703T1 (sl) 2007-08-31
GB0130339D0 (en) 2002-02-06
ES2280606T3 (es) 2007-09-16
SV2004001441A (es) 2004-05-07
AU2002359378B2 (en) 2008-08-21
WO2003053948A1 (en) 2003-07-03
AU2002359378B8 (en) 2008-09-11
AU2002359378A1 (en) 2003-07-09
CA2469278A1 (en) 2003-07-03
EP1458703A1 (en) 2004-09-22
PT1458703E (pt) 2007-05-31
JP2005516952A (ja) 2005-06-09
PE20030728A1 (es) 2003-08-29
TW200301116A (en) 2003-07-01
CY1106552T1 (el) 2012-01-25
CN1620447A (zh) 2005-05-25
AR038662A1 (es) 2005-01-26
DK1458703T3 (da) 2007-06-11
DE60218529T2 (de) 2007-11-22
DE60218529D1 (de) 2007-04-12
ATE355283T1 (de) 2006-03-15
BR0214859A (pt) 2004-11-03
EP1458703B1 (en) 2007-02-28

Similar Documents

Publication Publication Date Title
CN101155804B (zh) 用于治疗精神疾病的哌嗪取代的苯并噻吩
KR0167349B1 (ko) 벤조헤테로 고리 화합물
JP4272423B2 (ja) ドーパミンｄ３受容体のモジュレーターとして有用なテトラヒドロベンズアゼピン誘導体（抗精神病剤）
CN103880827B (zh) 芳基和杂芳基取代的四氢异喹啉及其阻断去甲肾上腺素、多巴胺和血清素的重摄取的应用
KR100191258B1 (ko) 치료제로서 유용한 3-아릴카르보닐-1h-인돌 및 그의 제조방법
JP2007514690A (ja) ヒスタミンｈ３アンタゴニストとしてのベンズアゼピン誘導体
KR20020067548A (ko) 선택적인 뉴로키닌 길항제
HUP0104280A2 (hu) Dopamin D3 receptorok modulátoraiként felhasználható tetrahidrobenzazepin-származékok, eljárás az előállításukra, a vegyületeket tartalmazó gyógyszerkészítmények
JP2005523310A (ja) 置換インドール
CN101128457A (zh) 凝血酶受体拮抗剂
TW201629051A (zh) 用於治療疾病之硫酸乙醯肝素生物合成抑制劑
WO2009009411A1 (en) Substituted heterocyclic ethers and their use in cns disorders
EP3538528A1 (en) Pyrrole amides as alpha v integrin inhibitors
WO2009092276A1 (zh) 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
RU2414454C2 (ru) N, n-замещенные 3-аминопирролидиновые соединения, полезные в качестве ингибиторов повторного поглощения моноаминов
US20040122001A1 (en) Pharmaceutical compounds
CA2521400A1 (en) Piperazine derivative renin inhibitors
CN1312148C (zh) 用于治疗中枢神经系统疾病的异色满化合物
AU2021410119A1 (en) Tetrahydroquinoline derivative and medicinal use thereof
JP2008502644A (ja) ヒスタミンｈ３アンタゴニストとしての３−シクロアルキルベンズアゼピン
JP2001058989A (ja) ピリミジン誘導体およびその塩
US7335660B2 (en) Isochroman compounds for treatment of CNS disorders
TWI437985B (zh) 雙環取代吡唑酮偶氮類衍生物、其製備方法及其在醫藥上的應用
CN118974013A (zh) 吡咯烷化合物
HK40033080B (zh) 大环衍生物、其制备方法以及包含其的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1077810

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070425

Termination date: 20101206